Dyadic Appoints Sales Director to Senior Management Team | Nation / World

JUPITER, Fla., November 09, 2021 (GLOBE NEWSWIRE) – Dyadic International, Inc. (“Dyadic”, “we”, “our”, “our” or the “Company”) (NASDAQ: DYAI), a global biotechnology focused on the enhancement, application and deployment of its proprietary C1 cellular protein production platform to accelerate development, reduce production costs, and improve performance of biological vaccines, therapeutics and others Protein Products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this position supports the global commercialization of the Company’s new and existing business initiatives, including corporate strategy, business and corporate development and licensing. Mr. Hazelton will join Dyadic’s management team reporting directly to President and CEO Mark Emalfarb.

“We are delighted to welcome Joe Hazelton to our leadership team in this important role as we enter this critical phase in the development of Dyadic’s business. We are continuing our search for cutting-edge scientific and strategic partnerships to expand the application of our C1 protein expression and manufacturing platform. The addition of Joe to lead our business efforts reinforces our commitment to maximize the integration of the C1 platform in life sciences and pharmacy, in addition to opportunities in other industries, ”said Mark Emalfarb.

“I am delighted to join Dyadic International as Chief Business Officer. The vast utility of the C1 platform is truly transformational across many industries. As such, Dyadic is uniquely positioned to take advantage of growing organic markets, while at the same time exploiting strategic opportunities within animal health and other market segments. I have been impressed by the commitment of the accomplished management team and board of directors of Dyadic International in their efforts to accelerate the adoption of C1 technology in global healthcare and related industries, and I am honored to have the opportunity to be a part of this future, ”said Hazelton.

Mr. Hazelton brings to Dyadic over 20 years of pharmaceutical industry experience in the key growth areas of product and business development, licensing and commercialization. He joins Dyadic from Charleston Laboratories, Inc. where he served as COO and Commercial Director, responsible for the strategic management of Charleston product and portfolio management, alliance management, oversight regulatory and global marketing activities. Prior to Charleston, Mr. Hazelton began his career with Novartis Pharmaceuticals Corporation, where, for 15 years, he held positions of increasing responsibility based on his leadership, innovation and results. At Novartis, Joe has held leadership roles in core sales, marketing, market access, pricing, contracts and strategic alliances for various retail and specialty pharmaceuticals in a wide range of therapeutic areas and several successful products.

Mr. Hazelton received a Bachelor of Arts from the College of the Holy Cross in Worcester, MA, and resides in Florida with his wife and two children.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company developing what it believes to be a potentially important biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables large-scale low-cost protein development and manufacture, has the potential to be further developed into a safe and efficient expression system that can help accelerate development, reduce production costs and improve the performance of organic products. vaccines and drugs at flexible commercial scales. Dyadic uses C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacture of human and animal vaccines and drugs, such as virus particles (VLPs) and antigens, antibodies monoclonal, fragments of antibodies Fab, Fc-fusion proteins, biosimilars and / or biomeillers, and other therapeutic proteins. Some other research activities are ongoing, including exploring the use of C1 to develop and produce certain metabolites and other biologicals. Dyadic pursues research and development collaborations, licensing agreements and other business opportunities with its partners and collaborators to leverage the value and benefits of these technologies in the development and manufacture of biopharmaceuticals. As the aging population grows in both developed and underdeveloped countries, Dyadic believes C1 technology can help bring vaccines, drugs and other biologicals to market faster, in larger volumes, at lower cost, and with new properties for drug developers and manufacturers, and improve access and costs for patients and the healthcare system, but most importantly, save lives.

Please visit Dyadic’s website at http://www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s expectations, intentions, strategies and beliefs. International regarding future or future events. financial performance. Actual events or results may differ materially from forward-looking statements due to a variety of material factors, including those described in the Company’s most recent SEC documents. Dyadic assumes no obligation to publicly update such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section titled “Risk Factors” in Dyadic’s Annual Reports on Form 10-K and Quarterly Reports on the Form 10-Q filed with the SEC, as these factors may be updated from time to time in Dyadic’s periodic files with the SEC, which are available on the SEC website and at http: / /www.dyadic.com.

Contact:

Dyadique International, Inc.

Ping W. Rawson

Financial director

Telephone: (561) 743-8333

Email: [email protected]

Copyright 2021 GlobeNewswire, Inc.

Comments are closed.